- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00560118
Fotemustine in Treating Patients With Metastatic Melanoma
Phase II Study of the Predictive Value of the Expression of Tumoral MGMT With Respect to the Therapeutic Response of Fotemustine in Patients With Metastatic Malignant Melanoma
RATIONALE: Drugs used in chemotherapy, such as fotemustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment.
PURPOSE: This phase II trial is studying fotemustine to see how well it works in treating patients with metastatic melanoma.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
OBJECTIVES:
Primary
- Assess the relationship between MGMT expression and response to fotemustine in patients with metastatic malignant melanoma.
Secondary
- Establish a value for MGMT expression below which fotemustine has a strong probability of effectiveness.
OUTLINE: This is a multicenter study.
Patients receive induction chemotherapy comprising fotemustine IV over 1 hour on days 1, 8, and 15. Beginning 5 weeks later, patients achieving stable or objective response receive maintenance chemotherapy comprising fotemustine IV over 1 hour once every 3 weeks for 6 courses.
Tissue samples are collected at baseline to assess level of MGMT expression by PCR.
After completion of study treatment, patients are followed every 2 months.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Montpellier, Frankrig, 34298
- Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
DISEASE CHARACTERISTICS:
Histologically confirmed metastatic malignant melanoma, meeting the following criteria:
- Metastatic lymph nodes or skin allowing for surgical resection
- At least 1 metastatic lesion (lymph nodes, skin, visceral, brain)
- Measurable or evaluable disease
PATIENT CHARACTERISTICS:
- WHO performance status 0-2
- ANC > 2 x 10^9/L
- Platelet count > 100 x 10^9/L
- Transaminases ≤ 2.5 times normal
- Alkaline phosphate ≤ 2.5 times normal
- Total bilirubin normal
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No severe uncontrolled infection
- No other prior or concurrent malignancy (except basal cell or squamous cell carcinoma in situ of the cervix that was curatively treated)
PRIOR CONCURRENT THERAPY:
- No prior chemotherapy
- At least 2 weeks since prior adjuvant therapy
- At least 4 weeks since prior radiotherapy
- At least 30 days since prior participation in another clinical trial
- No prior or concurrent prophylactic phenytoin
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
---|
Relationship between MGMT expression and response to fotemustine
|
Sekundære resultatmål
Resultatmål |
---|
Value for MGMT expression below which fotemustine has a strong probability of effectiveness
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studiestol: Didier Cupissol, MD, PhD, Institut du Cancer de Montpellier - Val d'Aurelle
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CDR0000574147
- CLCC-MGFOT-1
- INCA-RECF0287
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Melanom (hud)
-
Alma LasersTrukket tilbageSkin ResurfacingForenede Stater
-
R2 DermatologyAfsluttet
-
Syneron MedicalAfsluttetSkin Resurfacing | RynkereduktionForenede Stater, Canada
-
University of Split, School of MedicineAfsluttetSkin Recovery i forskellige humane hudskademodellerKroatien
-
National Cancer Institute (NCI)ExelisisAfsluttetStage IV Uveal Melanoma AJCC v7 | Tilbagevendende uveal melanom | Stage III Uveal Melanoma AJCC v7 | Stage IIIA Uveal Melanoma AJCC v7 | Stadie IIIB Uveal Melanoma AJCC v7 | Stage IIIC Uveal Melanoma AJCC v7Forenede Stater, Canada
-
Centre Hospitalier le MansRekruttering
-
The First Affiliated Hospital of Dalian Medical...UkendtSår og skader | Trauma | Brud, åben | Skin ExpanderKina
-
Integrative Skin Science and ResearchBurt's Bees Inc.RekrutteringAcne | Skin MicroboimeForenede Stater
-
National Cancer Institute (NCI)AfsluttetFase IV kutan melanom AJCC v6 og v7 | Tilbagevendende melanom | Fase IIIC kutan melanom AJCC v7 | Slimhinde melanom | Iris melanom | Fase IIIA kutan melanom AJCC v7 | Fase IIIB kutan melanom AJCC v7 | Stage IV Uveal Melanoma AJCC v7 | Medium/Large Size Posterior Uveal Melanom | Tilbagevendende uveal melanom | Stage IIIA Uveal Melanoma AJCC v7 og andre forholdForenede Stater
-
PT. Daewoong InfionEquilab InternationalAfsluttetHudtransplantatar | Split-Thickness Skin Graft (STSG)Indonesien
Kliniske forsøg med genekspressionsanalyse
-
Pusan National University HospitalAfsluttet
-
Liao Jian AnRekrutteringHoved- og halskræftTaiwan
-
Fondation LenvalTrukket tilbage
-
Daniel MarotiWayne State UniversityRekrutteringSomatisk symptomlidelse | Funktionel somatisk lidelse | Funktionelle somatiske syndromerSverige
-
Kessler FoundationIkke rekrutterer endnuAutismespektrumforstyrrelse
-
Candela CorporationRekrutteringMeibomisk kirtel dysfunktion | Tør øjensygdomForenede Stater, Argentina
-
IRCCS Eugenio MedeaRekrutteringAutismespektrumforstyrrelse | Tidlig indsatsItalien
-
Oregon Health and Science University4DMedicalTilmelding efter invitationLungesygdomme | KOL | Luftvejssygdom | DyspnøForenede Stater
-
IRCCS Eugenio MedeaRekrutteringCerebral Parese | Erhvervet hjerneskadeItalien
-
Muğla Sıtkı Koçman UniversityAfsluttet